Sustained-Release Erythropoietin Ameliorates Cardiac Function in Infarcted Rat–Heart Without Inducing Polycythemia

Xue Lin, MD; Masatoshi Fujita, MD*; Naoki Kanemitsu, MD; Yu Kimura, MD**; Keiichi Tambara, MD; Goditha U. Premaratne, MD; Atsushi Nagasawa, MD; Tadashi Ikeda, MD; Yasuhiro Tabata, PhD**; Masashi Komeda, MD

**Background**  The usefulness of sustained-release erythropoietin for improving left ventricular (LV) function without polycythemia was evaluated in a rat chronic myocardial infarction model.

**Methods and Results**  Four weeks after left coronary artery ligation, 50 Sprague-Dawley rats were assigned to 5 groups (n=10, each). Control group had a gelatin sheet (20×20mm) containing saline applied to the infarct area, whereas the 4 treatment groups had gelatin sheets incorporating erythropoietin 0.1U, 1U, 10U and 100U, respectively. Endpoint measurements performed at 8 weeks after the coronary ligation revealed that the fractional area change was larger for erythropoietin 1U and 10U than in the other 3 groups. The LV end-systolic elastance and the time constant of isovolumic relaxation were better for erythropoietin 1U and 10U than in the other 3 groups. The density of vessels larger than 50μm in diameter was the highest in the erythropoietin 1U group. The number of red blood cells was significantly increased in groups receiving erythropoietin 10U and 100U.

**Conclusions**  Gelatin hydrogel sheets incorporating 1U erythropoietin improved LV function without inducing polycythemia in a rat chronic myocardial infarction model. (*Circ J* 2007; 71: 132–137)

**Key Words:** Angiogenesis; Chronic myocardial infarction; Erythropoietin; Sustained-release; Ventricular remodeling

Recent advances in coronary reperfusion strategies and pharmaceutical management have resulted in an increasing number of survivors of acute myocardial infarction (AMI) who have a higher risk of developing left ventricular (LV) remodeling and chronic heart failure. Although therapeutic approaches aimed at delivering blood flow to the myocardium at risk are needed to improve cardiac function and prevent progression of LV remodeling, some patients have no revascularization options because of the diffuse nature of their coronary artery lesions. In such patients, therapeutic angiogenesis is being explored as an alternative strategy for providing significant blood flow to the akinetic myocardial tissue. Although initial uncontrolled clinical studies of therapeutic angiogenesis have generated a great deal of hope, the effectiveness of angiogenic growth factor has not been confirmed by subsequent randomized trials.1,2

As a result, delivery strategies to achieve clinically significant angiogenic responses with sustained-release (SR) angiogenic growth factors are being explored.3-5 Recently, we developed a biodegradable gelatin hydrogel sheet incorporating basic fibroblast growth factor (bFGF), which enabled the bFGF to be released at the site of action for a sufficient time period.6,7

Several recent studies have demonstrated that erythropoietin (EPO) has protective effects against ischemic injury in the brain, spinal cord, retina, kidney, and most recently, in the myocardium.13-17 EPO treatment has been reported to improve cardiac function in a post-infarction heart failure model.18-20 However, systemic treatment with a large dose of EPO is accompanied by polycythemia as an endogenous function of EPO, which may predispose to thromboembolic complications.15,18

Thus, in the present study, we aimed to develop a biodegradable gelatin hydrogel sheet incorporating EPO and to determine the appropriate dose of EPO for improving LV function without inducing polycythemia in a rat chronic myocardial infarction (MI) model.

**Methods**

Male Sprague-Dawley rats were used in this study. All experimental procedures were performed in accordance with the guidelines for Animal Experiments of Kyoto University, which conforms to the law of “Guide for the Care and Use of Laboratory Animals” in Japan and conforms to the “Guide for the Care and Use of Laboratory Animals” published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).

**Preparation of Gelatin Hydrogel Sheets Incorporating EPO**

Gelatin was prepared through an acid process of pig skin type I collagen and kindly supplied by Nitta Gelatin, Osaka, Japan. Gelatin hydrogel sheets were made using the pre-
Previously described process. Sheets were freeze-dried and cut in a rectangular shape for impregnation with phosphate buffered saline containing EPO (3,000 U in 0.5 ml, Sigma, Tokyo, Japan) at room temperature for 3 h. The prepared EPO-incorporating gelatin hydrogel sheets were used immediately after preparation.

In Vivo Evaluation of EPO Release and Gelatin Hydrogel Sheet Degradation

Gelatin hydrogels incorporating 125I-labeled EPO were implanted subcutaneously into the dorsum of the mice, and 100 μl of subcutaneously injected aqueous solution of 125I-labeled EPO was used as a control. The mice were killed at various intervals, and the skin around the EPO-implant or injection site was cut into strips. The fascia was thoroughly wiped with filter paper and the remaining radioactivity of the gelatin hydrogel, excised skin, and filter paper was measured on a gamma counter (ARC-301B; Aloka Co Ltd, Tokyo, Japan) to evaluate the time profile of in vivo degradation of the gelatin hydrogels.

Chronic MI Model

MI was created in rats weighing 250–290 g by ligating the proximal left anterior descending (LAD) coronary artery through a left thoracotomy, as described in our previous reports. Four weeks after the LAD ligation, infarction size and cardiac function were evaluated by means of echocardiography and cardiac catheterization, as described below.

Experimental Groups

Four weeks after the coronary artery ligation, 50 rats with moderate-sized MI were assigned to 5 groups (each group, n=10). Group I, which had a saline-incorporated gelatin hydrogel sheet, served as the controls, and groups 2–5 had gelatin hydrogel sheets incorporating 0.1 U, 1 U, 10 U and 100 U of EPO, respectively. In each group, the rectangular gelatin hydrogel sheet was stabilized to the LV wall with 6-0 polypropylene sutures to cover the area of MI completely.

Echocardiography

Echocardiography assessment was performed according to the method previously described. In brief, LV dimension and function were assessed just before treatment, and followed up 2 and 4 weeks later. Images were recorded using a 10–12 MHz phased array transducer (Model 21380A with HP SONOS 5500 imaging system, Agilent Technologies, Andover, MA, USA). LV end-diastolic and end-systolic dimensions (LVDd and LVDs, respectively) were measured with M-mode tracings from the short-axis view of the LV at the papillary muscle level. Fractional area change (FAC) and the percentage of akinetic endocardial length to the whole LV endocardial circumference (AL) were also calculated from the same short-axis view. All measurements were performed in a blind fashion according to the American Society of Echocardiology, and averaged over 3 consecutive cardiac cycles.

Cardiac Catheterization

After the final echocardiographic evaluation, the rats underwent cardiac catheterization for more precise assessment of global LV function as described previously. In brief, under general anesthesia, a 2F micromanometer-tipped catheter (Millar Instruments Inc, Houston, TX, USA) was inserted via the right carotid artery into the LV, and a 3F occlusion balloon catheter through the right femoral vein into the inferior vena cava. LV pressure and its first time-derivative (dp/dt) were continuously monitored using a multiple recording system. The LV end-systolic volume was calculated from the M-mode echocardiograms by the cube formula. During the inferior vena cava occlusion with the balloon, pressure waveforms and M-mode tracings were simultaneously recorded, and the end-systolic elastance (Ees) and the time constant of isovolumic relaxation (Taur) were derived from the recorded data. In calculating Ees, the end-systolic pressure–volume points obtained from echocardiography and cardiac catheterization were subjected to linear regression. All data were acquired under stable conditions.

Analysis of Vascular Density

After the final hemodynamic assessment, all rats were killed for the histological study. The specimens were paraffin-embedded, and the whole hearts were sectioned in 3 μm thickness at 100 μm intervals along the short axis. In the peri-MI area, the number of vessels was counted in each heart using immunohistochemistry for von Willebrand factor (U0034; Dako A/S, Glostrup, Denmark). The vessels per 1 mm² in the pertinent zone were counted in 3 randomly chosen fields per slide in a blind manner and averaged for statistical analysis.
Measurement of Red Blood Cells (RBC)

Blood samples were obtained from a peripheral tail vein of sedated rats at 0, 2, and 4 weeks after the treatment. Samples were analyzed using a Celltac (Model MEK-6358, NIHON KODEN, Japan).

Data Analysis

All data are expressed as the mean ± standard error of the mean. Comparisons of echocardiographic data and the number of RBC among the groups were performed by 2-way repeated measures analysis of variance (ANOVA) including time, group, and group-by-time interaction terms. Comparisons of cardiac catheterization data and vascular density among the groups were conducted by one-way factorial ANOVA. All statistical analyses were performed using computer software (StatView for Windows version 5.0, SAS Institute Inc, Cary, NC, USA). A p-value <0.05 was considered statistically significant.

Results

Both the mortality after coronary artery ligation and the size of the MI were similar to our previous reports.26,27

EPO Concentration by Gelatin Sheet Treatment

Fig 1 depicts the time course of remaining radioactivity of 125I-labeled EPO after subcutaneous injection of EPO solution or subcutaneous implantation of gelatin hydrogels sheet incorporating EPO. More than 95% of the EPO injected as solution was cleared from the injected site within 1 day, whereas there was a prolonged release of EPO from the hydrogel at the site of implantation.

Echocardiography

There were no significant differences among the 5 groups in any data for cardiac function at 4 weeks after coronary artery ligation (Table 1). In the analyses of LVDd and LVDs, group and time effects and group-by-time interactions were strongly recognized. At 4 weeks after each treatment, LVDd in the groups with EPO 1 U and 10 U was significantly smaller than in the control group and the groups with EPO 0.1 U and 100 U. The groups with EPO 1 U and 10 U had significantly smaller LVDs than the control group. In addition, in groups with EPO 1 U and 10 U, FAC was significantly larger and AL was significantly smaller than in the control group and groups with EPO 0.1 U and 100 U.

Table 1 Echocardiographic Data

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>0.1 U</th>
<th>1 U</th>
<th>10 U</th>
<th>100 U</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LVDd (cm)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before</td>
<td>1.06±0.06</td>
<td>1.09±0.06</td>
<td>1.07±0.05</td>
<td>1.08±0.07</td>
<td>1.07±0.08</td>
</tr>
<tr>
<td>After</td>
<td>1.12±0.02*</td>
<td>1.12±0.04</td>
<td>1.01±0.02*</td>
<td>1.04±0.03*</td>
<td>1.10±0.02</td>
</tr>
<tr>
<td><strong>LVDs (cm)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before</td>
<td>0.87±0.07</td>
<td>0.88±0.06</td>
<td>0.86±0.06</td>
<td>0.87±0.09</td>
<td>0.86±0.05</td>
</tr>
<tr>
<td>After</td>
<td>0.94±0.02*</td>
<td>0.94±0.04*</td>
<td>0.81±0.02*</td>
<td>0.84±0.04*</td>
<td>0.88±0.02</td>
</tr>
<tr>
<td><strong>FAC (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before</td>
<td>33.7±2.6</td>
<td>34.0±4.0</td>
<td>33.8±4.3</td>
<td>33.4±3.9</td>
<td>33.2±2.3</td>
</tr>
<tr>
<td>After</td>
<td>25.9±1.9*</td>
<td>29.0±2.7*</td>
<td>39.0±1.5*</td>
<td>35.9±2.7*</td>
<td>28.3±1.2</td>
</tr>
<tr>
<td><strong>AL (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before</td>
<td>25.7±3.3</td>
<td>27.0±2.5</td>
<td>25.3±3.0</td>
<td>26.6±3.1</td>
<td>26.1±2.5</td>
</tr>
<tr>
<td>After</td>
<td>30.9±1.5*</td>
<td>28.6±2.3</td>
<td>21.0±0.6*</td>
<td>23.6±1.8*</td>
<td>27.1±1.8</td>
</tr>
</tbody>
</table>

* Values are mean ± SEM.
EPO, erythropoietin; LVDd, left ventricular end-diastolic dimension; LVDs, left ventricular end-systolic dimension; FAC, fractional area change; AL, percentage of akinetic endocardial length to the whole left ventricular endocardial circumference.

EPO, erythropoietin; † p<0.05 vs control; ‡ p<0.05 vs EPO 0.1 U; ¶ p<0.05 vs EPO 100 U.
One-way factorial ANOVA showed a high group effect in both Ees and Tau (Fig 2). The Ees was the highest in the group with EPO 1 U (control: 0.12±0.01, EPO 0.1 U: 0.14±0.02, EPO 1 U: 0.33±0.08, EPO 10 U: 0.30±0.08, EPO 100 U: 0.15±0.02 mmHg/mL, respectively). Also, the Tau was the lowest in the group with EPO 1 U among them (control: 19.7±0.9, EPO 0.1 U: 19.3±1.0, EPO 1 U: 16.6±0.6, EPO 10 U: 16.9±0.8, EPO 100 U: 19.7±1.3 ms).

Vascular Density

Representative images are shown in Fig 3. The vascular density in the peri-MI area was highest in the group with EPO 1 U (control, EPO 0.1 U, 1 U, 10 U, 100 U: 13.68±2.49, 21.08±2.75, 37.97±4.19, 24.42±6.07, 21.54±4.68/mm², respectively). The vascular density in the group with EPO 10 U was significantly higher than in the control group (24.42±6.07 vs 13.68±2.49/mm²; p<0.05) (Fig 4).

RBC Analysis

In the groups with EPO 10 U and 100 U, the number of RBC at 4 weeks after treatment was significantly higher than in the control group. The number of RBC in the groups with EPO 0.1 U and 1 U was comparable with the control group (Fig 5) (control, EPO 0.1 U, 1 U, 10 U, 100 U; pretreatment baseline: 832±22, 827±15, 842±17, 832±27, 825±32×10⁴/μL; 4 weeks: 826±19, 798±15, 801±21, 949±30, 989±28×10⁴/μL).

Discussion

The salient findings of this study are as follows: (1) the SR system with EPO enabled release of EPO from a gelatin hydrogel sheet over a period greater than 3 weeks, and (2) the most relevant dose of EPO incorporated in the sheet for
improving LV function without inducing polycythemia was 1 U in the rat chronic MI model.

It is pertinent to comment on reasons why we used SR EPO sheets rather than gelatin hydrogel microspheres incorporating EPO. In our earlier studies, gelatin hydrogel microspheres28–31 and sheets6,7 were used as a carrier of SR bFGF. For the purpose of healing of devascularized sternum, we used gelatin sheets incorporating bFGF, for anatomical reasons6,7 but in the case of MI, we injected a solution of 100 U containing gelatin bFGF microspheres into several sites of the border zones of MI scar tissue28,29. There are several limitations to that therapeutic approach. First, intramyocardial injection itself may injure the myocardium. Second, the thin scar tissue may limit the appropriate space for microsphere retention. Finally, it is difficult to determine the local concentration of released bFGF in situ. Epicardial application of gelatin sheets may overcome these disadvantages and in fact, gelatin hydrogel sheets incorporating other angiographic growth factors are being used in experimental settings24,25. An epicardial application of a bone-marrow-cell-seeded biodegradable polymeric scaffold is reported to be useful for enhancing angiogenesis and improving myocardial function in the infarcted heart.35

It is tempting to speculate about how EPO suppresses LV remodeling and ameliorates LV contractility and relaxation after MI. There are 3 possible mechanisms responsible for the reduction of functional decline after MI (ie, progression in the LV observed in rats of the control group in the present study). First of all, augmented angiogenesis might contribute to functional recovery after MI. In the present study, the vascular density in the peri-MI area was positively correlated with FAC and Ezs, and negatively correlated with AL and Tau. Although a good correlation does not necessarily indicate a cause–effect relationship, it is conceivable that EPO-induced angiogenesis might ameliorate LV functional recovery. Our speculation is supported by the fact that EPO accelerates naturally occurring capillary overgrowth as powerfully as vascular endothelial growth factor33. Second, favorable effects with EPO may result from its ability to reduce apoptotic cell death. It has been demonstrated that the number of apoptotic cardiomyocytes in the infarct area was decreased significantly by EPO treatment in a rat AMI model14,15,19 although EPO administration did not affect the apoptosis of cardiomyocytes in a rat chronic MI model18. This discrepancy may be explained by the fact that apoptotic cell death tapers with the progression of pathological changes of MI34. In fact, in the present study reported here, approximately 0.1% nuclei of cardiomyocytes were TUNEL positive in the area at risk of untreated hearts at 8 weeks after coronary artery ligation. Thus, the contribution toward prevention of apoptosis by EPO treatment may be minimal, if any, in our experimental model. Another beneficial effect of EPO treatment may be its anti-inflammatory effects via attenuation of pro-inflammatory cytokine production35. However, it is difficult to specify these favorable effects to EPO, because prevention of LV remodeling by EPO treatment may result in subsidence of the inflammatory response to myocardial ischemic injury.

Previous investigators have attempted to find the optimal EPO dose for improving LV function without inducing polycythemia in the chronic MI model. van der Meer et al produced LV functional improvement with intraperitoneal EPO administration at a dose of 8,000 U/kg18; however, significant polycythemia inevitably occurred. In contrast, a single intravenous injection of 1,000 U/kg EPO did not improve LV function36. Thus, it is difficult to determine the therapeutically useful EPO dose in the chronic MI model. Our therapeutic approach with a SR drug delivery system overcame these problems of EPO treatment. Indeed, when a 1 U EPO gelatin sheet was applied, the plasma EPO concentration was augmented by less than 0.5%, which is negligible in comparison with the more than 100-fold increase in the case of a single intraperitoneal EPO injection at a dose of 8,000 U/kg19. Thus, the clinical application of EPO treatment for chronic MI is promising with the use of this newly developed drug delivery system.

It deserves some comment why the 100 U EPO did not improve the endpoints. As shown in Fig 2, myocardial function was most improved with 1 U EPO treatment, and it showed a gradual deterioration with increasing doses of EPO. The dose-independency may be, at least in part, explained by the fact that polycythemia associated with 10 U and 100 U EPO treatment may disturb the microcirculation in the infarcted area because of the high blood viscosity. Further studies are necessary to elucidate the paradoxical dose-dependency with EPO treatment.

Study Limitations

For gelatin hydrogel sheet application, re-opening the chest is inevitable at 4 weeks after AMI, which is more invasive than a single intravenous injection of EPO. The disadvantage may be counterbalanced by combined coronary artery bypass grafting surgery. Another limitation to the clinical application of the new treatment strategy is the relatively narrow window of optimal doses with EPO. To overcome these drawbacks, clinical studies are needed to determine the optimal dose of EPO in humans.

In future, we need to conduct double-blind, randomized controlled clinical trials to establish the effects of SR EPO treatment on surrogate markers such as LV ejection fraction, myocardial perfusion and exercise tolerance in patients with ungrafted viable myocardium.

In conclusion, application of gelatin hydrogel sheets incorporating 1 U EPO successfully reversed LV remodeling without inducing polycythemia in the rat chronic MI model. This new treatment strategy to treat ischemic cardiomyopathy will be realized in the clinical setting in the near future.

Acknowledgments

We would like to express our sincere gratitude to Mrs Fumiyo Kataoka for her expert technical assistance, and acknowledge the meticulous assistance of Miss Yukiko Okamura during the preparation of this manuscript.

References

5. Grines CL, Watkins MW, Mahmariin JJ, Iskandrian AE, Rade JJ,


